Launching a therapy has become increasingly challenging, with only 34% of launches meeting their year-one goals (Evaluate Pharma, McKinsey). In addition, launches have also become more complex, with additional stakeholders to consider as well as the careful navigation of siloed, enterprise-wide functions and dynamic, fragmented data solutions. Not surprisingly, the path to a successful launch can be very narrow.
As the US healthcare system has shifted in recent years from a “volume-to-value” framework, there is increasing pressure on the industry to demonstrate the value of innovative therapies early in development, particularly those for diseases that present a large societal burden or for which there remains significant unmet need. The urgency to innovate underscores the importance of strategic partnering: cross-industry collaborations to support evidence generation that will, in turn, advance medical care and health outcomes.
Have you heard about ICER’s new research protocol for assessing price increases of prescription drugs in California? PRECISIONheor’s Jacki Chou kicks off our new Insights90 series by breaking down this new protocol.
This month, PRECISIONheor highlights Vice President Patrick Sullivan, PhD.
This month PRECISIONheor highlights the newest addition to the team, Senior Research Scientist, Rozanne Wilson, PhD.
This month PRECISIONheor would like to highlight the newest addition to the team, Vice President Alice Pressman.
There's been increasing interest in using Health Technology Assessment to guide coverage decisions and health policies. Recently, the COVID-19 experience has provided important lessons for value assessment of new interventions and its communication to stakeholders.
Real-world data are important sources within health care resource utilization (HCRU) research, but these databases often are repurposed for this use rather than custom designed. Some researchers are beginning to collect HCRU data within the context of clinical trials, with the intention to address research questions of interest, rather than relying solely on data salvaged from insurance claims or electronic health records.
Using a multi-disciplinary, mixed methods approach to evidence generation, PRECISIONheor has an established track record of quantifying the value of treatment and communicating insights capturing the perspectives of key stakeholders.
Want a glimpse at some of the insightful real-world evidence publications that PRECISIONheor experts have recently contributed to in order to help get life-saving treatments into the hands of patients that need them the most?
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
